Statement: Unlike the secondary trial, the primary trial only provides the duration of cycles and drug doses in the intervention section.
Primary_evidence: INTERVENTION 1:    CMRM vs UMRM [Not Specified]
Secondary_evidence: INTERVENTION 1:    A: Exemestane   ARM A: Patients will be treated with exemestane.   Exemestane: 25 mg daily by mouth for 6 to 12 months. INTERVENTION 2:    B: Docetaxel and Cytoxan   ARM B: Patients will be treated with docetaxel and cytoxan.   Docetaxel: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).   Cytoxan: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).